Literature DB >> 20597976

The in vivo distribution of brain tissue loss in Richardson's syndrome and PSP-parkinsonism: a VBM-DARTEL study.

Federica Agosta1, Vladimir S Kostić, Sebastiano Galantucci, Sarlota Mesaros, Marina Svetel, Elisabetta Pagani, Elka Stefanova, Massimo Filippi.   

Abstract

In this study, we wished to test, using magnetic resonance imaging and voxel-based morphometry (VBM), whether specific cortical and subcortical patterns of brain grey (GM) and white matter (WM) tissue loss can be detected in patients with Richardson's syndrome (PSP-RS) and progressive supranuclear palsy-parkinsonism (PSP-P), and possibly account for their clinical heterogeneity. Twenty patients with PSP, classified as PSP-RS (10 patients) or PSP-P (10 patients), and 24 healthy controls were studied. The Statistical Parametric Mapping (SPM5) and the Diffeomorphic Anatomical Registration using Exponentiated Lie algebra method were used to perform a VBM analysis. Compared with controls, both patient groups showed GM loss in the central midbrain, cerebellar lobes, caudate nuclei, frontotemporal cortices and right hippocampus. WM loss was detected in both conditions in the midbrain, left superior cerebellar peduncle, internal capsulae, and left premotor and bilateral prefrontal regions. Compared with PSP-P, patients with PSP-RS showed additional regions of GM loss in the midbrain, left cerebellar lobe and dentate nuclei. PSP-RS was also associated with a more severe WM loss in the midbrain, internal capsulae, and orbitofrontal, prefrontal and precentral/premotor regions, bilaterally. Patients with PSP-P showed a more pronounced GM loss only in the frontal cortex, bilaterally. This study shows that, albeit the overall pattern of brain atrophy associated with PSP appears remarkably consistent across the spectrum of clinical features recorded in life, major anatomical differences between these two conditions do exist. Such a different topographical distribution of tissue damage may account for the clinical differences between PSP-RS and PSP-P.

Entities:  

Mesh:

Year:  2010        PMID: 20597976     DOI: 10.1111/j.1460-9568.2010.07304.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  31 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

2.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.

Authors:  Jennifer L Whitwell; Jia Xu; Jay N Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2011-11-13       Impact factor: 4.891

3.  The relationship between clinical and pathological variables in Richardson's syndrome.

Authors:  Emma C Schofield; John R Hodges; Thomas H Bak; John H Xuereb; Glenda M Halliday
Journal:  J Neurol       Date:  2011-08-12       Impact factor: 4.849

4.  Magnetic resonance imaging in progressive supranuclear palsy.

Authors:  M Stamelou; S Knake; W H Oertel; G U Höglinger
Journal:  J Neurol       Date:  2010-12-22       Impact factor: 4.849

Review 5.  Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy.

Authors:  Keita Sakurai; Aya M Tokumaru; Keigo Shimoji; Shigeo Murayama; Kazutomi Kanemaru; Satoru Morimoto; Ikuko Aiba; Motoo Nakagawa; Yoshiyuki Ozawa; Masashi Shimohira; Noriyuki Matsukawa; Yoshio Hashizume; Yuta Shibamoto
Journal:  Neuroradiology       Date:  2017-04-06       Impact factor: 2.804

6.  In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism.

Authors:  Karin Srulijes; Grit Mallien; Sarah Bauer; Elisabeth Dietzel; Adriane Gröger; Georg Ebersbach; Daniela Berg; Walter Maetzler
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

7.  Phosphorylated α-synuclein in Parkinson's disease.

Authors:  Yu Wang; Min Shi; Kathryn A Chung; Cyrus P Zabetian; James B Leverenz; Daniela Berg; Karin Srulijes; John Q Trojanowski; Virginia M-Y Lee; Andrew D Siderowf; Howard Hurtig; Irene Litvan; Mya C Schiess; Elaine R Peskind; Masami Masuda; Masato Hasegawa; Xiangmin Lin; Catherine Pan; Douglas Galasko; David S Goldstein; Poul Henning Jensen; Hui Yang; Kevin C Cain; Jing Zhang
Journal:  Sci Transl Med       Date:  2012-02-15       Impact factor: 17.956

8.  Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: Multivariate and univariate analyses in American and Chinese patient cohorts.

Authors:  Jingjie Ge; Jianjun Wu; Shichun Peng; Ping Wu; Jian Wang; Huiwei Zhang; Yihui Guan; David Eidelberg; Chuantao Zuo; Yilong Ma
Journal:  Hum Brain Mapp       Date:  2018-03-13       Impact factor: 5.038

Review 9.  Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies.

Authors:  Hai Cun Shi; Jian Guo Zhong; Ping Lei Pan; Pei Rong Xiao; Yuan Shen; Li Juan Wu; Hua Liang Li; Yuan Ying Song; Gui Xiang He; Hong Ye Li
Journal:  Neurol Sci       Date:  2013-03-30       Impact factor: 3.307

10.  Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy.

Authors:  J L Whitwell; J R Duffy; E A Strand; M M Machulda; M L Senjem; J L Gunter; K Kantarci; S D Eggers; C R Jack; K A Josephs
Journal:  Eur J Neurol       Date:  2012-10-18       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.